Vaccine

United States Clostridium Vaccine Market 2019-2024 by Bovine, Ovine, Poultry, Swine, Other Animals - ResearchAndMarkets.com

Friday, November 15, 2019 - 2:22pm

The "United States Clostridium Vaccine Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Clostridium Vaccine Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The country research report on the United States clostridium vaccine market is a customer intelligence and competitive study of the United States market.
  • The report on the United States clostridium vaccine market provides a detailed analysis of segments in the market based on animal type, and distribution channel.
  • 5) What are the modes of entering the United States clostridium vaccine market?

United States Human Papillomavirus Vaccine Market Report 2019: Prospects, Trends Analysis, Market Size and Forecasts up to 2024 - ResearchAndMarkets.com

Thursday, November 14, 2019 - 8:17pm

The "United States Human Papillomavirus Vaccine Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Human Papillomavirus Vaccine Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The report on the United States human papillomavirus vaccine market provides a detailed analysis of segments in the market based on product type, indication, and distribution channel.
  • The companies and dealers/distributors profiled in the report include manufacturers & suppliers of human papillomavirus vaccine market in the United States.
  • 5) What are the modes of entering the United States human papillomavirus vaccine market?

Global therapeutic BCG vaccines market is expected to grow with a CAGR of 4.5% over the forecast period from 2019-2025

Thursday, November 14, 2019 - 1:15pm

The report on the global therapeutic BCG vaccines market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Key Points: 
  • The report on the global therapeutic BCG vaccines market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The report predicts the global therapeutic BCG vaccines market to grow with a CAGR of 4.5% over the forecast period from 2019-2025.
  • The study on therapeutic BCG vaccines market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.
  • The report on therapeutic BCG vaccines market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global therapeutic BCG vaccines market over the period of 2017 to 2025.

GeoVax to Present at Vaccines R&D Conference

Thursday, November 14, 2019 - 2:00pm

During the conference, Dr. Guirakhoo will also serve as a panelist for a session discussing the development of vaccines for the current Ebola crisis.

Key Points: 
  • During the conference, Dr. Guirakhoo will also serve as a panelist for a session discussing the development of vaccines for the current Ebola crisis.
  • Importantly, MVA vaccines elicit protective T cell as well as antibody responses in animals and humans.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented MVA-VLP based vaccine platform.
  • The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

Phase 3 Results of Bavarian Nordic’s Smallpox Vaccine Published in The New England Journal of Medicine

Thursday, November 14, 2019 - 7:23am

The vaccine, marketed as JYNNEOS, is indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older.

Key Points: 
  • The vaccine, marketed as JYNNEOS, is indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older.
  • We are very proud that our research has been acknowledged by The New England Journal of Medicine.
  • The fact that the study results have been published by such an esteemed journal underpins the importance of the data to the medical community, said Paul Chaplin, President and CEO of Bavarian Nordic.
  • The study, which compared indicators of efficacy for Bavarian Nordics non-replicating smallpox vaccine, MVA-BN to ACAM2000, the U.S. licensed, replicating smallpox vaccine, successfully achieved both co-primary endpoints, while also demonstrating an improved safety profile versus ACAM2000.

AHF Lauds WHO’s Belated Pre-Qualification of the Ebola Vaccine

Thursday, November 14, 2019 - 2:21am

AHF has been calling for an approved vaccine for more than a yeareven before the current outbreak in the DRC (Democratic Republic of the Congo) began last August.

Key Points: 
  • AHF has been calling for an approved vaccine for more than a yeareven before the current outbreak in the DRC (Democratic Republic of the Congo) began last August.
  • Were glad the WHO has finally pre-qualified itunfortunately, this is bittersweet because it has taken entirely too long given the devastation that Ebola brings and the clear evidence of the vaccines efficacy, said AHF President Michael Weinstein.
  • The success of the first trial for the Merck Ebola vaccine, rVSV-ZEBOV, was first reported in the Lancet in July 2015 .
  • The WHO pre-qualification comes on the heels of vaccines approval by the European Commission , which makes it the first officially approved Ebola vaccine in the world.

CrazyMothers to Host November 14 Event on National Mall to Honor Unsung Victims of Vaccine Injury

Wednesday, November 13, 2019 - 9:34pm

Thousands will gather on the National Mall on November 14 to raise awareness for vaccine injury and honor those whose lives have been impacted by vaccine reactions, injury and death.

Key Points: 
  • Thousands will gather on the National Mall on November 14 to raise awareness for vaccine injury and honor those whose lives have been impacted by vaccine reactions, injury and death.
  • The event marks the day that the National Childhood Vaccine Injury Act (NCVIA) was enacted 33 years ago, ultimately removing manufacturer liability for vaccine injury and death and creating a government compensation program for those affected.
  • Organized by CrazyMothers, a nonprofit advocacy group, the event seeks to honor those whose lives have been harmed by government-licensed and recommended vaccines.
  • is twofold: to illustrate that vaccine injury is prevalent not one in a million as is commonly cited and to give a voice to the voiceless.

Valneva Announces Appointments of Two Leading Vaccine Experts to its Scientific Advisory Board

Wednesday, November 13, 2019 - 5:00pm

Saint Herblain (France), November 13, 2019 Valneva SE (Valneva or the Company), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB).

Key Points: 
  • Saint Herblain (France), November 13, 2019 Valneva SE (Valneva or the Company), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB).
  • Prior to his position as Director, Dr. Baylor served as Deputy Director of OVRR and Associate Director for Regulatory Policy.
  • Dr. Baylor continues to serve as an expert advisor to the World Health Organization on several global vaccine initiatives.
  • Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 490 employees.

Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Tuesday, November 12, 2019 - 9:45pm

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.
  • Vaxart plans to focus its efforts and resources on progressing the clinical development of its oral tableted bivalent norovirus vaccine.
  • Financial Results for the Three Months Ended September 30, 2019
    Vaxart reported a net loss of $5.3 million for the third quarter of 2019 compared to $6.5 million for the third quarter of 2018.
  • Vaxart ended the quarter with cash and cash equivalents of $19.6 million compared to $16.3 million at June 30, 2019.

NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)

Tuesday, November 12, 2019 - 2:00pm

AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing authorization to ERVEBO, investigational V920 Ebola Zaire vaccine (rVSVG-ZEBOV-GP) , as confirmed by our partner, Merck (NYSE:MRK), known as MSD outside the US and Canada.

Key Points: 
  • AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing authorization to ERVEBO, investigational V920 Ebola Zaire vaccine (rVSVG-ZEBOV-GP) , as confirmed by our partner, Merck (NYSE:MRK), known as MSD outside the US and Canada.
  • With this approval, the EC will grant a centralized marketing authorization for the vaccine with unified labeling that is valid in 31 European countries.
  • As NewLink has previously stated, the FDAs approval of this Ebola vaccine would trigger the issuance of a priority review voucher owned by Merck and in which NewLink Genetics has a substantial economic interest.
  • NewLink Genetics is a clinical-stage biopharmaceutical company that has historically focused on developing novel immunotherapeutic products for the treatment of patients with cancer.